# DESCRIPTION

## STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

- describe government rights

## BACKGROUND

- introduce immune checkpoint blockade

## SUMMARY

- introduce PD-1 inhibitors
- describe limitations of mAb drugs
- motivate small-molecule inhibitors
- describe PD-L1 binding cavity
- introduce substituted variant of human PD-1
- describe crystallization and X-ray crystallography
- identify prominent pocket on ligand-binding surface
- describe structure of PD-L2 binding pocket
- introduce drug discovery methods
- describe computational screening
- describe computational identification of ligands
- describe computational docking
- introduce proteins with ligand binding pocket
- describe amino acid substitutions
- describe removal of N-linked glycosylation sites
- introduce variants of human PD-1
- describe crystal forms of proteins
- introduce methods for identifying small molecules
- describe in silico docking
- describe evaluation of candidate small molecules
- describe interactions with PD-L2 binding pocket
- describe hydrogen bonds
- describe ionic interactions
- describe water-mediated interactions
- describe π-π interactions
- describe van der Waals interactions
- describe steric interactions
- describe non-endogenous ligands
- describe binding forces
- describe configurational entropy
- describe Gibbs free energy landscape
- describe energy barriers
- introduce in silico method
- describe molecular dynamic simulations
- describe kinetic Monte Carlo simulations
- describe direct simulations Monte Carlo
- describe density functional theory simulations
- describe computational docking
- describe scoring and binning

## DETAILED DESCRIPTION

- introduce PD-1 receptor
- describe PD-1 ligands
- motivate identification of new ligands
- describe limitations of current methods
- summarize previous attempts to determine PD-1 structure
- describe stabilization of PD-1/PD-L2 complex
- determine structure of PD-1/PD-L2 binding pocket
- describe application of structure in drug discovery
- exemplify drug discovery process
- describe computational screening of compounds
- describe testing of potential leads
- describe importance of in silico lead identification
- provide exemplary amino acid sequence of human PD-1 protein
- describe structures of human triple-mutant PD-1/PD-L2 complex
- describe apo triple-mutant PD-1 variant
- summarize conformational changes of CC′ and FG loops
- motivate design and discovery of small-molecule PD-1 inhibitors
- describe advantages of small-molecule inhibitors
- describe limitations of current small-molecule ligands
- describe in vivo binding of PD-1 to PD-L1 and PD-L2
- describe formation of cavity on ligand-binding surface of PD-1
- describe difficulties in obtaining human PD-1/PD-L2 complex structure
- describe realization of allosteric effect of CC′ and FG loops
- describe application of pocket in virtual drug discovery

### Terms and Concepts

- define terms and concepts
- facilitate understanding of embodiments
- clarify terms based on accepted conventions
- define singular and plural terms
- describe nomenclatures used
- specify enzymatic reactions and purification techniques
- define "a", "an", and "the"
- define "or" and "and/or"
- define "another"
- abbreviate amino acid residues
- define "ligand"
- describe interaction types
- define nonbonded interaction types
- define bonded interactions
- describe entropic-based interactions
- define hydrogen-bonding
- describe hydrogen bond donors and acceptors
- define ionic bonding
- define van der Waals interaction
- define π-π interaction or π-π stacking
- describe steric interactions
- define binding site
- describe binding pocket
- define molecular descriptors
- describe chemical descriptors
- describe physical descriptors
- describe geometrical descriptors
- describe environmental descriptors
- assign chemical descriptors
- describe data representations
- define affinity formulation
- describe energy model
- choose affinity formulation
- describe computation strategy
- define computation strategy
- describe direct summation
- describe probe grid map approximation
- describe hybrid computation strategy
- define affinity function
- describe affinity components
- analyze molecular combination
- determine configuration with best value
- consider multiple favorable values
- compute multiple affinity functions
- define "about" and "approximately"
- describe acceptable degree of error
- define small molecule

### Drug Design and Discovery

- define drug design and discovery subprocesses
- motivate target validation
- describe lead generation
- explain lead optimization
- outline preclinical testing
- discuss clinical trials and approval
- introduce laboratory methods for measuring affinity
- limitations of laboratory methods
- motivate computational methods for molecular interactions
- introduce rational drug design

### Computational Methods

- introduce rational drug design
- motivate structure-based drug design
- describe three-dimensional model of target structure
- derive three-dimensional model from X-ray crystallography/NMR
- derive three-dimensional model from homology modeling
- describe structure-based in silico design
- describe testing and optimization of human PD-1 ligands
- motivate computational modeling of target-ligand molecular interactions
- describe lead optimization
- describe computational prediction of desired drug-like biological properties
- introduce library screening
- describe computational modeling of target-ligand molecular combinations
- rank ligands based on computational prediction of bioactivity
- introduce fragment-based drug discovery
- describe identifying starting points for drug development
- describe growing or combining fragments to produce leads
- determine three-dimensional binding mode of fragments
- facilitate optimization into leads with higher activity
- combine FBLD with screening
- define binding mode
- define binding energy
- describe optimal binding free energy
- describe binding affinity
- motivate understanding of binding mode and affinity
- introduce docking
- introduce scoring
- describe trade-offs between computational complexity and resources
- describe molecular dynamics simulations
- describe rigid-body pattern-matching algorithms
- describe fragmental-based methods
- describe stochastic optimization methods
- describe hybrids strategies
- introduce software tools for docking simulations
- describe incremental construction based docking software tools
- describe stochastic optimization-based methods
- describe molecular dynamics simulations in lead discovery
- introduce scoring functions
- describe empirical scoring functions
- describe molecular-mechanics-based scoring functions
- introduce knowledge-based scoring functions
- describe DrugScore, PMF, and BLEEP
- explain assumptions of knowledge-based scoring functions
- introduce concept of singlet preferences
- describe hybrid scoring functions
- explain consensus scoring
- discuss file formats for structural and chemical information
- introduce calculation of total electrostatic energies
- describe classical formalisms for electrostatic desolvation
- discuss full quantum mechanical treatment of electrostatics interactions
- illustrate modeling system 100
- describe configuration modeler 102
- explain affinity calculator 109
- describe descriptor data storage 120
- discuss usage of modeling system 100
- explain sampling of configurations
- describe selection strategy for configuration sampling
- discuss assessment of molecular combination
- explain implementation of modeling system 100
- describe storage media devices
- discuss software processing components
- explain configuration selector 112
- describe feedback cycle
- discuss combination postprocessor 116
- explain generation of combination measures
- describe selection of configurations
- discuss statistical analysis of configuration results
- explain pattern-matching methods
- describe combination results records
- discuss dynamic application of combination postprocessor 116
- explain ranking of configurations
- describe removal of configuration records
- discuss molecular combination record database 104
- explain input molecule records
- describe input target record database and input ligand record database
- discuss input target molecular records
- explain input ligand molecular records
- describe configuration data transformation engine 108
- explain transformation of molecular configurations
- discuss unary, binary, and n-ary operations
- describe construction of new configurations
- explain search and optimization techniques
- discuss iterative process
- describe stochastic search strategy
- explain descriptor data storage 120

### In Vitro and In Vivo Methods

- describe in vitro and in vivo methods for drug design and discovery
- determine biological activity of candidate compounds in vitro
- validate in silico predicted activities with in vitro biological assay results
- validate in silico predicted activities with in vivo study results
- describe in vitro platform for evaluating ability of candidate compounds to block PD-1 interaction
- describe bioluminescent cell-based assay for screening and profiling inhibitors of PD-1:PD-L2 interaction
- describe competition ELISA for evaluating ability of candidate compounds to block PD-1 interaction
- describe assay for testing biological activity of candidate compounds
- describe assay for promoting T cell function
- describe other in vitro assays for evaluating biological activity of candidate compounds
- describe in vitro assay for measuring IL-2 secretion by PBMC
- describe mixed lymphocyte response assay
- describe assay for measuring nonspecific T cell activation
- describe studies of potential anti-cancer effects of candidate compounds in vitro
- describe in vivo assays using mouse models
- describe tumor measurement and candidate compound administration in mice
- describe T-cell depletion studies
- describe immune response monitoring
- describe intracellular staining and cytokine assays
- describe immunohistochemical studies of tumor sections
- describe determining toxicity of ligand in in vitro, in vivo, or in silico assay

### Computer Systems

- describe computer systems and subsystems
- describe interconnection of subsystems via system bus
- describe peripherals and input/output devices
- describe connection to wide area network
- describe computer readable medium
- describe implementation of embodiments using hardware and software
- describe software components and functions
- describe storage and transmission of software code
- describe computer readable medium for storage and transmission
- describe computer system configured to perform steps of methods

## EXAMPLES

- introduce examples of the claimed invention

### Example 1: Materials and Methods

- describe yeast-surface display
- describe bio-layer interferometry
- describe protein crystallization and X-ray crystallography

### Example 2: Engineering Human PD-1 Loop Variants with Enhanced PD-L2 Affinity

- motivate directed evolution of PD-1 loop variants
- describe construction of loop-variant libraries
- describe selection of high-affinity variants
- describe characterization of PD-1 loop variants

### Example 3: PD-1 Loop Variants Showed Increased Binding Affinity and Association Kinetics for PD-L2 and PD-L1

- describe validation of enhanced affinity of PD-1 loop variants
- describe binding of PD-L2 to wild-type PD-1 and variants
- describe fitting of binding curves
- describe kinetic measurements of binding

### Example 4: X-Ray Crystal Structure of the Human PD-1/PD-L2 Complex

- describe crystallization of human PD-1/PD-L2 complex
- describe structure determination
- describe architecture of human PD-1/PD-L2 complex
- describe validation of interactions at PD-1/PD-L2 interface

### Example 5: X-Ray Crystal Structures of Human Apo-PD-1 Loop Variants

- describe crystallization and structure determination of apo-PD-1 loop variants
- describe conformational change of PD-1 associated with PD-L2 binding

### Example 6: Formation of a Prominent Pocket in Human PD-1 Upon Binding PD-L2, with Human PD-1 Pocket Having Architecture Distinct from that of Murine PD-1 Pocket

- describe formation of human PD-1 pocket upon binding PD-L2
- describe architecture of human PD-1 pocket
- describe comparison of human and murine PD-1 pockets
- describe pocket dimensions
- describe structural plasticity of human PD-1 ligand-binding interface

### Example 7: The CC′ Loop in the Triple-Mutant PD-1 Adopts a Ligand-Bound Conformation in the Absence of Ligand

- describe conformational changes in CC′ and FG loops upon binding PD-L2
- describe ligand-bound conformation of CC′ loop in apo-PD-1 triple mutant

### Example 8: Structural plasticity of the human PD-1 ligand-binding interface

- describe structural plasticity of human PD-1 ligand-binding interface

### Example 9: Coordinates and Structure Factors

- describe coordinates and structure factors for human PD-1/PD-L2 complex and apo-PD-1 loop variants

